Skip to main content

Aspira Women's Health Inc.

AWHL
Exchange
OTC
Industry
In Vitro & In Vivo Diagnostic Substances
SEC CIK
0000926617

No open-market purchases or sales by Aspira Women's Health Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.

Q3 2024 vs. Q2 2024

How the institutions holding Aspira Women's Health Inc. changed between Q2 2024 and Q3 2024.

All holders in Q3 2024All holders in Q2 2024

13F holders of AWHL: Q2 2024 compared with Q3 2024
MeasureQ2 2024Of which not filed for Q3 2024Q3 2024Change
Holders261250
Shares1.40M73.4K2.35M+1.03M (+78.0%)
Value$2.08M$109.3K$1.91M−$62.8K (−3.2%)

1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.

New holders (5)

Institutions that held Aspira Women's Health Inc. at the end of Q3 2024 but not at the end of Q2 2024.

Institutions new to AWHL in Q3 2024
InstitutionSharesValue% of portfolio
BlackRock, Inc.83,502$67.6K0.00%
Pine Valley Investments Ltd Liability Co31,200$25.3K0.00%
Millennium Management LLC16,000$13.0K0.00%
Virtu Financial LLC12,575$10.0K0.00%
Danske Bank A/S1$10.00%

Sold out (5)

Institutions that held Aspira Women's Health Inc. at the end of Q2 2024 and filed for Q3 2024 without it.

Institutions that sold out of AWHL in Q3 2024
InstitutionShares, Q2 2024Value, Q2 2024
Squarepoint Ops LLC12,328$18.4K
Citadel Advisors LLC11,754$17.5K
HRT Financial LP10,903$16.0K
Royal Bank of Canada2,348$3.00K
Castleview Partners, LLC1,316$1.96K

Not filed for Q3 2024 yet (1)

Institutions that held Aspira Women's Health Inc. at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding AWHL in Q2 2024 that haven't filed for Q3 2024
InstitutionShares, Q2 2024Value, Q2 2024
BlackRock Inc.73,380$109.3K